Prévalence et facteurs de risque de la rétinopathie drépanocytaire dans un centre de suivi drépanocytaire d’Afrique subsaharienne

Dembélé, A; Touré, Boubacari Ali; Sarro, Yeya Sadio; Guindo, Aldiouma; Fané, Baba; Offredo, Lucile; Sekou, Kene; Conaré, I.; Tessougué, O.; Traoré, Youssouf; Badiaga, Youssouf; Sidibe, M.; Diabaté, D T; Coulibaly, Massa; Kanta, M.; Ranque, Brigitte; Diallo, Dapa A.

doi:10.1016/j.revmed.2017.01.010

Cited by 20 publications

(20 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whether the earlier diagnosis of patients born in France was associated with a less severe visual prognosis was unclear because blindness was very rare in our cohort, and the laser coagulation prevalence was identical. A study conducted in a referral center in Mali (n = 1064 patients, mean age of 24.2 years) in which patients were screened for retinopathy starting at an age of 10 years estimated its presence to be 8.8% in SCD individuals over the age of 10 years regardless of their genotype, with a maximal prevalence of 12.4% among S/C patients [19]. The prevalence reported in our Africa-born patients (49.1%) was much higher, but their mean age was 9 years older (33.2 ± 10.7).…”

Section: Discussionmentioning

confidence: 99%

Comparison between Adult Patients with Sickle Cell Disease of Sub-Saharan African Origin Born in Metropolitan France and in Sub-Saharan Africa

Honsel

Khimoud

Ranque

et al. 2019

JCM

View full text Add to dashboard Cite

Sickle cell disease (SCD) prevalence has increased rapidly in Europe as a result of an increase in the life expectancy of these patients and the arrival of SCD migrants from Africa. The aim of our study was to compare the phenotypes of adult patients born in Sub-Saharan Africa (SSA) who migrated to France with those of patients with the same origin who were born in France. This single-center observational study compared the demographic, clinical and biological characteristics of SCD adult patients of SSA origin who were born in France or SSA. Data were collected from computerized medical charts. Groups were compared using multivariate logistic regression with adjustment for age, gender and type of SCD. Of the 323 SCD patients followed in our center, 235 were enrolled, including 111 patients born in France and 124 patients born in SSA. SCD genotypes were balanced between groups. Patients born in Africa were older (median age 32.1 (24.4–39) vs. 25.6 (22.1–30.5) years, p < 0.001) and more often women (n = 75 (60.5%) vs. 48 (43.2%), p = 0.008). The median age at arrival in France was 18 years (13–23). The median height was lower among patients born in SSA (169 (163–175) vs. 174.5 cm (168–179), p < 0.001). Over their lifetimes, patients born in France had more acute chest syndromes (median number 2 (1–4) vs. 1 (0–3), p = 0.002), with the first episode occurring earlier (19 (11.6–22.3) vs. 24 (18.4–29.5) years, p < 0.007), and were admitted to intensive care units more often (53.3% vs. 34.9%, p = 0.006). This difference was more pronounced in the SS/Sβ0 population. Conversely, patients born in SSA had more skin ulcers (19.4% vs. 6.3%, p = 0.03). No significant differences were found in social and occupational insertion or other complications between the two groups. Patients born in SSA had a less severe disease phenotype regardless of their age than those born in France. This difference could be related to a survival bias occurring in Africa during childhood and migration to Europe that selected the least severe phenotypes.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison between Adult Patients with Sickle Cell Disease of Sub-Saharan African Origin Born in Metropolitan France and in Sub-Saharan Africa

Honsel

Khimoud

Ranque

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…Taken together, PSCR is rarer than NPSCR in SCD patients, but PSCR is diagnosed more frequently in SC patients than in SS patients. 9 , 15 , 16 , 26 , 27 …”

Section: Classification and Epidemiology Of Scrmentioning

confidence: 99%

“…Ophthalmologic screening of SCD patients should involve a number of basic exams as well as the use of state-of-the-art retinal imaging techniques when available/possible due to their relative high cost. 9 , 16 , 20 , 47 , 48 , 55 , 56 Thus, routine screening of ocular abnormalities for earliest detection and intervention of retinopathy should include visual acuity testing (to measure the clarity or sharpness of vision at a distance of 20 feet), complete dilated funduscopy, as well as the use of slit-lamp biomicroscopy (to observe any ocular abnormalities in the anterior portion of the eye and eventual retinal detachments). In case of abnormal funduscopy, 16 , 34 patient cases with ischemic retinopathy often undergo FA 9 , 16 , 17 , 51 , 56 , 57 or OCTA.…”

Section: Prevention and Diagnosis Of Scrmentioning

confidence: 99%

“…5 , 7 In Brazil, the frequency reaches up to 0.06% depending on the different regions, 8 whereas in Africa, the frequency is the highest in the world, varying from 5% to 40%. 9 , 10 …”

Section: Introductionmentioning

confidence: 99%

“… 13 HbSC patients often present blood flow abnormalities due to hypercoagulable Hb, 14 and are associated with advanced SCR although visual impairment is SCD genotype independent. 9 , 15 , 16 Besides, SCT is considered benign but can become a pathologic risk factor for marked retinopathy (ie, vaso-occlusive features and retinal proliferative changes). SCR in HbAS patients can occur in few weeks under conditions of stress, concomitant systemic diseases, or trauma (eg, blunt ocular trauma, scarring) leading to hypoxia, independent of raised intraocular pressure.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Sickle cell retinopathy: improving care with a multidisciplinary approach

Menaa¹,

Khan²,

Uzair³

et al. 2017

JMDH

View full text Add to dashboard Cite

Sickle cell retinopathy (SCR) is the most representative ophthalmologic complication of sickle cell disease (SCD), a hemoglobinopathy affecting both adults and children. SCR presents a wide spectrum of manifestations and may even lead to irreversible vision loss if not properly diagnosed and treated at the earliest. Over the past decade, multidisciplinary research developments have focused upon systemic, genetic, and ocular risk factors of SCR, enabling the clinician to better diagnose and manage these patients. In addition, newer imaging and testing modalities, such as spectral domain-optical coherence tomography angiography, have resulted in the detection of subclinical retinopathy related to SCD. Innovative therapy includes intravitreal injection of an anti-vascular endothelial growth factor (eg, Lucentis® [ranibizumab] or Eylea® [aflibercept]) which appears comparatively safe and efficient, and may be combined with laser photocoagulation (LPC) for proliferative SCR. The effect of LPC alone does not significantly lead to the regression of advanced SCR, although it helps in avoiding hemorrhage and sight loss. This comprehensive article is based on 10-years retrospective (2007–2017) studies. It aims to present advances and recommendations in SCR theranostics while pointing out the requirement of combinatorial approaches for better management of SCR patients. To reach this goal, we identified and analyzed randomized original and review articles, clinical trials, non-randomized intervention studies, and observational studies using specified keywords in various databases (eg, Medline, Embase, Cochrane, ClinicalTrials.gov).

show abstract

Neutrophils in sickle cell disease: Exploring their potential role as a therapeutic target

de Ligt,

Gaartman,

Biemond

et al. 2024

American J Hematol

View full text Add to dashboard Cite

Sickle cell disease (SCD) is an inherited hemoglobinopathy characterized by chronic hemolytic anemia and recurrent microvascular occlusions, resulting in acute painful events and progressive organ damage. Although primarily a red blood cell disorder, the pathophysiology of SCD is increasingly characterized as a complex interplay between several different cell types and cellular processes. Evidence is accumulating that neutrophils are phenotypically different in SCD and have a significant contribution in the pathophysiology of the disease. In this review, we summarize the currently available evidence on the role of neutrophils in SCD pathophysiology, demonstrating that neutrophils in SCD have an activated phenotype and play an important role in vaso‐occlusion and inflammation in SCD. Activation of neutrophils in SCD is primarily driven by hemolysis and ischemia–reperfusion injury. The ameliorating effects of treatments, for example, hydroxyurea, might be partly mediated by decreasing neutrophil counts and reversing the pro‐inflammatory properties. Whether the novel anti‐sickling therapies, reducing hemolysis, have an anti‐inflammatory effect on neutrophils, remains to be elucidated.

show abstract

Prévalence et facteurs de risque de la rétinopathie drépanocytaire dans un centre de suivi drépanocytaire d’Afrique subsaharienne

Cited by 20 publications

References 24 publications

Comparison between Adult Patients with Sickle Cell Disease of Sub-Saharan African Origin Born in Metropolitan France and in Sub-Saharan Africa

Comparison between Adult Patients with Sickle Cell Disease of Sub-Saharan African Origin Born in Metropolitan France and in Sub-Saharan Africa

Sickle cell retinopathy: improving care with a multidisciplinary approach

Neutrophils in sickle cell disease: Exploring their potential role as a therapeutic target

Contact Info

Product

Resources

About